Camurus AB

Camurus AB, a Lund‑based biopharma, sells Buvidal and Brixadi for opioid disorders and boasts a robust pipeline—phase III CAM2029 (acromegaly), phase III CAM4072 (rare genetic obesity), phase II CAM2038 (chronic pain)—across Europe, NA and Asia.

Headquarters: Sweden (SWE)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 280
HQ: Lund

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
CAMX	Camurus AB Cap: 41.1B \| P/E: 52.9	EQUITY	STO	SEK	SE0007692850	Active	📈